$-0.11 EPS Expected for Cerus Corporation (CERS)

July 11, 2018 - By Pearl Odom

Investors sentiment increased to 1.84 in 2018 Q1. Its up 0.39, from 1.45 in 2017Q4. It is positive, as 5 investors sold Cerus Corporation shares while 27 reduced holdings. 21 funds opened positions while 38 raised stakes. 69.09 million shares or 17.19% more from 58.96 million shares in 2017Q4 were reported.
Bessemer Gp owns 0% invested in Cerus Corporation (NASDAQ:CERS) for 820 shares. Millrace Asset Gru stated it has 2.05% in Cerus Corporation (NASDAQ:CERS). Ubs Asset Americas accumulated 86,104 shares. Steinberg Global Asset Management stated it has 89,200 shares. Swiss Comml Bank accumulated 0% or 221,900 shares. Tci Wealth stated it has 4,150 shares. Northern Trust invested 0% of its portfolio in Cerus Corporation (NASDAQ:CERS). Garde Cap has 13,385 shares. Destination Wealth Management owns 180 shares. Zeke Cap Advsrs Limited Liability Corporation reported 14,328 shares. The Switzerland-based Credit Suisse Ag has invested 0% in Cerus Corporation (NASDAQ:CERS). Susquehanna Intll Grp Incorporated Ltd Liability Partnership reported 75,619 shares. 544,154 were reported by National Bank & Trust Of Ny Mellon Corp. Manufacturers Life Ins Com The owns 0% invested in Cerus Corporation (NASDAQ:CERS) for 96,089 shares. Prelude Capital Management Llc has 0.03% invested in Cerus Corporation (NASDAQ:CERS) for 73,316 shares.

Since March 10, 2018, it had 1 buy, and 11 sales for $1.32 million activity. Shares for $23,151 were sold by Moore Carol on Saturday, March 10. Another trade for 52,500 shares valued at $349,125 was sold by SCHULZE GAIL. Benjamin Richard J sold $57,722 worth of stock. On Monday, March 12 the insider CORASH LAURENCE M bought $773,199. Green Kevin Dennis sold 4,737 shares worth $23,409. ANDERSON TIMOTHY B sold $152,950 worth of stock or 23,000 shares.

Analysts expect Cerus Corporation (NASDAQ:CERS) to report $-0.11 EPS on August, 2.They anticipate $0.05 EPS change or 31.25 % from last quarter’s $-0.16 EPS. After having $-0.11 EPS previously, Cerus Corporation’s analysts see 0.00 % EPS growth. The stock decreased 0.99% or $0.07 during the last trading session, reaching $6.99. About 411,182 shares traded. Cerus Corporation (NASDAQ:CERS) has risen 221.29% since July 12, 2017 and is uptrending. It has outperformed by 208.72% the S&P500.

Cerus Corporation (NASDAQ:CERS) Ratings Coverage

Among 2 analysts covering Cerus Corp (NASDAQ:CERS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cerus Corp had 3 analyst reports since January 24, 2018 according to SRatingsIntel. Cantor Fitzgerald maintained it with “Buy” rating and $700 target in Tuesday, May 8 report. The rating was maintained by Cantor Fitzgerald with “Buy” on Thursday, March 8. Robert W. Baird maintained it with “Buy” rating and $6.0 target in Wednesday, January 24 report.

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company has market cap of $912.50 million. The Company’s INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. It currently has negative earnings. The company's INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion.

Another recent and important Cerus Corporation (NASDAQ:CERS) news was published by Globenewswire.com which published an article titled: “Report: Developing Opportunities within Torchmark, Cerus, American Equity Investment Life Holding, Southern Copper …” on June 28, 2018.

Cerus Corporation (NASDAQ:CERS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.